La vendita allo scoperto per Design Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Design Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Design Therapeutics (NASDAQ:DSGN) Azioni, Report sulle vendite allo scoperto

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc

Dayforce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) short percent of float has fallen 6.14% since its last report. The company recently reported that it has 14.68 million shares sold short, which is 14.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dayforce Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732546817_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dayforce has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dayforce's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dayforce's peer group average for short interest as a percentage of float is 5.31%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(DAY) - Analyzing Dayforce's Short Interest

In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) alongside its primary competitors in the Software industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
<h3>Microsoft Background</h3>
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft Corp</td>
<td>34.43</td>
<td>10.78</td>
<td>12.26</td>
<td>8.87%</td>
<td>$38.23</td>
<td>$45.49</td>
<td>16.04%</td>
</tr>
<tr>
<td>Oracle Corp</td>
<td>49.56</td>
<td>49.26</td>
<td>10.11</td>
<td>30.01%</td>
<td>$5.44</td>
<td>$9.4</td>
<td>6.86%</td>
</tr>
<tr>
<td>ServiceNow Inc</td>
<td>165.20</td>
<td>23.55</td>
<td>21.05</td>
<td>4.81%</td>
<td>$0.67</td>
<td>$2.21</td>
<td>22.25%</td>
</tr>
<tr>
<td>Palo Alto Networks Inc</td>
<td>49.72</td>
<td>21.28</td>
<td>16.43</td>
<td>6.33%</td>
<td>$0.45</td>
<td>$1.58</td>
<td>13.88%</td>
</tr>
<tr>
<td>CrowdStrike Holdings Inc</td>
<td>539.51</td>
<td>31.99</td>
<td>26.29</td>
<td>1.75%</td>
<td>$0.12</td>
<td>$0.73</td>
<td>31.74%</td>
</tr>
<tr>
<td>Fortinet Inc</td>
<td>46.62</td>
<td>78.30</td>
<td>12.53</td>
<td>90.26%</td>
<td>$0.66</td>
<td>$1.24</td>
<td>13.0%</td>
</tr>
<tr>
<td>Gen Digital Inc</td>
<td>30.49</td>
<td>8.87</td>
<td>4.94</td>
<td>7.92%</td>
<td>$0.51</td>
<td>$0.78</td>
<td>3.07%</td>
</tr>
<tr>
<td>Monday.Com Ltd</td>
<td>661.84</td>
<td>14.61</td>
<td>16.13</td>
<td>-1.28%</td>
<td>$-0.02</td>
<td>$0.23</td>
<td>32.67%</td>
</tr>
<tr>
<td>Dolby Laboratories Inc</td>
<td>29.94</td>
<td>3.10</td>
<td>6.15</td>
<td>2.39%</td>
<td>$0.07</td>
<td>$0.27</td>
<td>4.9%</td>
</tr>
<tr>
<td>CommVault Systems Inc</td>
<td>44.31</td>
<td>27.48</td>
<td>8.78</td>
<td>5.56%</td>
<td>$0.02</td>
<td>$0.19</td>
<td>16.06%</td>
</tr>
<tr>
<td>QXO Inc</td>
<td>29.89</td>
<td>1.54</td>
<td>27.24</td>
<td>-0.21%</td>
<td>$-0.03</td>
<td>$0.01</td>
<td>-2.0%</td>
</tr>
<tr>
<td>Qualys Inc</td>
<td>33.86</td>
<td>12.48</td>
<td>9.71</td>
<td>10.53%</td>
<td>$0.05</td>
<td>$0.13</td>
<td>8.36%</td>
</tr>
<tr>
<td>Teradata Corp</td>
<td>36.12</td>
<td>23.50</td>
<td>1.69</td>
<td>32.0%</td>
<td>$0.08</td>
<td>$0.27</td>
<td>0.46%</td>
</tr>
<tr>
<td>Progress Software Corp</td>
<td>37.23</td>
<td>6.98</td>
<td>4.30</td>
<td>6.88%</td>
<td>$0.06</td>
<td>$0.15</td>
<td>2.11%</td>
</tr>
<tr>
<td>SolarWinds Corp</td>
<td>60.27</td>
<td>1.66</td>
<td>2.90</td>
<td>0.94%</td>
<td>$0.07</td>
<td>$0.18</td>
<td>5.5%</td>
</tr>
<tr>
<td>Average</td>
<td>129.61</td>
<td>21.76</td>
<td>12.02</td>
<td>14.13%</td>
<td>$0.58</td>
<td>$1.24</td>
<td>11.35%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a meticulous analysis of Microsoft, we can observe the following trends: 
<ul>
<li>
At 34.43, the stock's Price to Earnings ratio is 0.27x less than the industry average, suggesting favorable growth potential.
</li>
<li>
The current Price to Book ratio of 10.78, which is 0.5x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
The Price to Sales ratio of 12.26, which is 1.02x the industry average, suggests the stock could potentially be overvalued in relation to its sales performance compared to its peers.
</li>
<li>
With a Return on Equity (ROE) of 8.87% that is 5.26% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $38.23 Billion is 65.91x above the industry average, highlighting stronger profitability and robust cash flow generation.
</li>
<li>
The company has higher gross profit of $45.49 Billion, which indicates 36.69x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
With a revenue growth of 16.04%, which surpasses the industry average of 11.35%, the company is demonstrating robust sales expansion and gaining market share.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732546818_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Microsoft can be compared to its top 4 peers, leading to the following observations:
<ul>
<li>
Microsoft has a stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.21.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be perceived as a positive indicator by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
The low PE and PB ratios suggest that Microsoft is undervalued compared to its peers in the Software industry. However, the high PS ratio indicates that the market values Microsoft's revenue more highly. In terms of profitability, Microsoft's low ROE may be a concern, despite its high EBITDA and gross profit margins. The high revenue growth rate reflects positively on Microsoft's future prospects within the industry.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Markets

MSFT

Assessing Microsoft's Performance Against Competitors In Software Industry

METROS DEVELOPMENT CO., LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRS#NASDAQ">MTRS</a>) IPO will take place November, 26 on the NASDAQ exchange under the ticker MTRS.
The company is offering shares at an expected price between $5.50 and $6.50 per share with an insider lock-up period of 180 days ending on May 25, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About METROS DEVELOPMENT CO., LTD.</h3>
METROS DEVELOPMENT CO., LTD is a real estate consulting company that identifies and purchases what we believe to be underdeveloped real estate properties (land and/or buildings) and re-sell such properties to real estate developers so that they can redevelop those properties.
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IPOs

MTRS

Preview: Metros Development Co., Ltd. Set To IPO Tomorrow

Beacon Roofing Supply's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NYSE">BECN</a>) short percent of float has risen 17.23% since its last report. The company recently reported that it has 1.67 million shares sold short, which is 3.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Beacon Roofing Supply Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732546812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Beacon Roofing Supply has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Beacon Roofing Supply's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Beacon Roofing Supply's peer group average for short interest as a percentage of float is 5.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BECN

How Is The Market Feeling About Beacon Roofing Supply?

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $216.5, with a high estimate of $250.00 and a low estimate of $188.00. A decline of 0.99% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1732546811_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of SPS Commerce among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinton Gabrielli</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$188.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SPS Commerce. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of SPS Commerce compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of SPS Commerce's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SPS Commerce's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPSC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SPS Commerce analyst ratings.</a>
<h2>All You Need to Know About SPS Commerce</h2>
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. Its products are; Fulfillment, Analytics, and Other products like Assortment and Community also it provides one-time services such as professional services and testing and certification. The group derives revenue from recurring monthly fees and set-up fees.
<h3>Key Indicators: SPS Commerce's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: SPS Commerce displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.66%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: SPS Commerce's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.06%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): SPS Commerce's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.53%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

SPSC

Unveiling 4 Analyst Insights On SPS Commerce

In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in relation to its major competitors in the Semiconductors &amp; Semiconductor Equipment industry. By closely examining crucial financial metrics, market position, and growth prospects, we aim to offer valuable insights for investors and shed light on company's performance within the industry.
<h3>NVIDIA Background</h3>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVIDIA Corp</td>
<td>56.04</td>
<td>52.75</td>
<td>31.16</td>
<td>31.13%</td>
<td>$22.86</td>
<td>$26.16</td>
<td>93.61%</td>
</tr>
<tr>
<td>Taiwan Semiconductor Manufacturing Co Ltd</td>
<td>30.52</td>
<td>8.04</td>
<td>12.10</td>
<td>8.36%</td>
<td>$555.05</td>
<td>$439.35</td>
<td>38.95%</td>
</tr>
<tr>
<td>Broadcom Inc</td>
<td>132.66</td>
<td>11.68</td>
<td>16.26</td>
<td>-2.77%</td>
<td>$6.39</td>
<td>$8.36</td>
<td>47.27%</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc</td>
<td>122.43</td>
<td>3.94</td>
<td>9.31</td>
<td>1.36%</td>
<td>$1.55</td>
<td>$3.42</td>
<td>17.57%</td>
</tr>
<tr>
<td>Texas Instruments Inc</td>
<td>36.80</td>
<td>10.46</td>
<td>11.57</td>
<td>7.86%</td>
<td>$2.09</td>
<td>$2.47</td>
<td>-8.41%</td>
</tr>
<tr>
<td>Qualcomm Inc</td>
<td>17.54</td>
<td>6.63</td>
<td>4.55</td>
<td>11.46%</td>
<td>$3.21</td>
<td>$5.78</td>
<td>18.69%</td>
</tr>
<tr>
<td>ARM Holdings PLC</td>
<td>224.82</td>
<td>23.77</td>
<td>40.87</td>
<td>1.83%</td>
<td>$0.11</td>
<td>$0.81</td>
<td>4.71%</td>
</tr>
<tr>
<td>Micron Technology Inc</td>
<td>146.63</td>
<td>2.52</td>
<td>4.57</td>
<td>1.99%</td>
<td>$3.63</td>
<td>$2.74</td>
<td>93.27%</td>
</tr>
<tr>
<td>Analog Devices Inc</td>
<td>64.64</td>
<td>3.03</td>
<td>11.04</td>
<td>1.11%</td>
<td>$1.04</td>
<td>$1.31</td>
<td>-24.84%</td>
</tr>
<tr>
<td>Microchip Technology Inc</td>
<td>46.31</td>
<td>5.71</td>
<td>6.60</td>
<td>1.24%</td>
<td>$0.34</td>
<td>$0.67</td>
<td>-48.37%</td>
</tr>
<tr>
<td>ON Semiconductor Corp</td>
<td>17.28</td>
<td>3.45</td>
<td>4.11</td>
<td>4.75%</td>
<td>$0.63</td>
<td>$0.8</td>
<td>-19.21%</td>
</tr>
<tr>
<td>Monolithic Power Systems Inc</td>
<td>65.48</td>
<td>12.05</td>
<td>13.93</td>
<td>6.35%</td>
<td>$0.17</td>
<td>$0.34</td>
<td>30.59%</td>
</tr>
<tr>
<td>STMicroelectronics NV</td>
<td>10.07</td>
<td>1.25</td>
<td>1.62</td>
<td>1.98%</td>
<td>$0.74</td>
<td>$1.23</td>
<td>-26.63%</td>
</tr>
<tr>
<td>ASE Technology Holding Co Ltd</td>
<td>19.80</td>
<td>2.27</td>
<td>1.19</td>
<td>3.16%</td>
<td>$28.59</td>
<td>$26.43</td>
<td>3.85%</td>
</tr>
<tr>
<td>First Solar Inc</td>
<td>16.02</td>
<td>2.62</td>
<td>5.19</td>
<td>4.22%</td>
<td>$0.45</td>
<td>$0.45</td>
<td>10.81%</td>
</tr>
<tr>
<td>United Microelectronics Corp</td>
<td>10.85</td>
<td>1.52</td>
<td>2.43</td>
<td>4.0%</td>
<td>$29.73</td>
<td>$20.43</td>
<td>5.99%</td>
</tr>
<tr>
<td>Skyworks Solutions Inc</td>
<td>23.15</td>
<td>2.16</td>
<td>3.30</td>
<td>0.95%</td>
<td>$0.18</td>
<td>$0.43</td>
<td>-15.9%</td>
</tr>
<tr>
<td>MACOM Technology Solutions Holdings Inc</td>
<td>129.33</td>
<td>8.65</td>
<td>13.56</td>
<td>2.67%</td>
<td>$0.05</td>
<td>$0.11</td>
<td>33.47%</td>
</tr>
<tr>
<td>Universal Display Corp</td>
<td>33.82</td>
<td>5.04</td>
<td>12.47</td>
<td>4.29%</td>
<td>$0.08</td>
<td>$0.13</td>
<td>14.57%</td>
</tr>
<tr>
<td>Lattice Semiconductor Corp</td>
<td>53.15</td>
<td>10.63</td>
<td>13.35</td>
<td>1.03%</td>
<td>$0.03</td>
<td>$0.09</td>
<td>-33.87%</td>
</tr>
<tr>
<td>Average</td>
<td>63.23</td>
<td>6.6</td>
<td>9.9</td>
<td>3.47%</td>
<td>$33.37</td>
<td>$27.12</td>
<td>7.5%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a thorough examination of NVIDIA, we can discern the following trends: 
<ul>
<li>
At 56.04, the stock's Price to Earnings ratio is 0.89x less than the industry average, suggesting favorable growth potential.
</li>
<li>
With a Price to Book ratio of 52.75, which is 7.99x the industry average, NVIDIA might be considered overvalued in terms of its book value, as it is trading at a higher multiple compared to its industry peers.
</li>
<li>
With a relatively high Price to Sales ratio of 31.16, which is 3.15x the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
With a Return on Equity (ROE) of 31.13% that is 27.66% above the industry average, it appears that the company exhibits efficient use of equity to generate profits.
</li>
<li>
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $22.86 Billion, which is 0.69x below the industry average, potentially indicating lower profitability or financial challenges.
</li>
<li>
Compared to its industry, the company has lower gross profit of $26.16 Billion, which indicates 0.96x below the industry average, potentially indicating lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 93.61% is notably higher compared to the industry average of 7.5%, showcasing exceptional sales performance and strong demand for its products or services.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732546810_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing NVIDIA against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
When considering the debt-to-equity ratio, NVIDIA exhibits a stronger financial position compared to its top 4 peers.
</li>
<li>
This indicates that the company has a favorable balance between debt and equity, with a lower debt-to-equity ratio of 0.16, which can be perceived as a positive aspect by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
The low P/E ratio suggests NVIDIA is undervalued compared to its peers in the Semiconductors &amp; Semiconductor Equipment industry. However, the high P/B and P/S ratios indicate that the market values the company's assets and sales more favorably. On the other hand, the high ROE and revenue growth, along with low EBITDA and gross profit, highlight potential for strong performance and growth in the future.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

Market Analysis: NVIDIA And Competitors In Semiconductors &amp; Semiconductor Equipment Industry

Creative Global Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) IPO will take place November, 26 on the NASDAQ exchange under the ticker CGTL.
The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on May 25, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About Creative Global Technology Holdings Limited</h3>
Creative Global Technology Holdings Limited Provides Professional Services Quality Products and aims to recycle reusable electronic products and provide qualified products to end-users.
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGTL

Preview: Creative Global Technology Holdings Limited Set To IPO Tomorrow

Over the past 24 hours, Avalanche's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>) price rose 8.6% to $43.33. This continues its positive trend over the past week where it has experienced a 26.0% gain, moving from $34.95 to its current price. As it stands right now, the coin's all-time high is $144.96. 
The chart below compares the price movement and volatility for Avalanche over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1732546806_0.png" alt="price_chart" />
Avalanche's trading volume has climbed 122.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.04%. This brings the circulating supply to 409.21 million, which makes up an estimated 56.83% of its max supply of 720.00 million. According to our data, the current market cap ranking for AVAX is #11 at $17.74 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1732546806_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$AVAX

Test0.25592340560400906: Avalanche Rises More Than 8% In 24 hours

Youxin Technology Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) IPO will take place November, 26 on the NASDAQ exchange under the ticker YAAS.
The company is offering shares at an expected price of $4.50 per share with an insider lock-up period of 180 days ending on May 25, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About Youxin Technology Ltd</h3>
a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses using our cloud-based SaaS product and PaaS platform to develop, use, and control business applications without the need to purchase complex IT infrastructure is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses using our cloud-based SaaS product and PaaS platform to develop, use, and control business applications without the need to purchase complex IT infrastructure.
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YAAS

Youxin Technology Ltd To Start Trading Tomorrow

QMCO

Quantum Corp Shares Resume Trade Following Circuit Breaker Halt

CMCSA

FUBO

Fubo Adds 18 NBCUniversal FAST Channels, Expanding Sports, Entertainment, News, And Latino Content With Telemundo Channels Launching Today

TD Cowen analyst Bill Katz maintains AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) with a Buy and raises the price target from $41 to $42.

Price Target

TD Cowen Maintains Buy on AllianceBernstein Holding, Raises Price Target to $42

AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares are trading higher. The company on Monday announced it saw its highest domestic revenue ever during the <a href="https://www.benzinga.com/pressreleases/24/11/b42164406/amc-theatres-total-revenue-domestically-on-the-pre-thanksgiving-weekend-is-the-highest-in-amcs-104">pre-Thanksgiving weekend</a>.
What Happened: AMC announced that it saw its highest domestic revenue, including admissions, food and beverage, in company history over the weekend. The pre-Thanksgiving weekend was the highest domestic admissions revenue since 2019 and the third highest domestic admissions revenue in AMC history. 
AMC welcomed 4.6 million moviegoers across all of its theaters in the U.S. and internationally from Thursday to Sunday. AMC said the attendance strength was driven by strong opening weekends from &#8220;Wicked&#8221; and &#8220;Gladiator II.&#8221; 
&#8220;This past weekend&#8217;s result is yet another demonstration that moviegoers want to see these films on the biggest screens, with the biggest sounds, and that theatrical exhibition is ready and able to support multiple blockbuster titles opening on the same weekend,&#8221; said Adam Aron, chairman and CEO of AMC Entertainment.
AMC noted that its merchandise program for &#8220;Wicked&#8221; was well received with collectibles selling out about halfway through the weekend. The company also announced that select AMC locations will offer &#8220;Wicked Singalong&#8221; showtimes starting in late December. 
AMC noted that it expects to remain busy heading into the Thanksgiving holiday weekend with the highly anticipated &#8220;Moana 2&#8221; release set for Wednesday. 
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/entertainment/24/11/42123085/wicked-gladiator-ii-moana-2-could-break-thanksgiving-weekend-box-office-stocks-to-watch">&#8216;Wicked,&#8217; &#8216;Gladiator II,&#8217; &#8216;Moana 2&#8217; Could Break Thanksgiving Weekend Box Office: Stocks To Watch</a>
AMC Price Action: <a href="http://benzinga.com/quote/amc">AMC shares</a> were up 4.95% at $4.77 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.flickr.com/photos/pasa/">Paul Sableman</a> from Flickr.

AMC Entertainment Stock Is Surging Monday: What's Going On?

<a href="https://x.com/michaelmokulr/status/1861060159709012283" title="https://x.com/michaelmokulr/status/1861060159709012283">https://x.com/michaelmokulr/status/1861060159709012283</a>

KULR

KULR Technology CEO & Co-Founder Michael Mo Posts On X "We're building the next digital energy management platform. More to come… in a bit. $KULR #digitalenergy"

<a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242002">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242002</a>
&nbsp;

Biotech

General

FEMY

Femasys Gets FDA 510(k) Substantially Equivalent Decision Of Its FemVue MINI Saline-Air Device On November 22, 2024

Digital asset investment products experienced their largest <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42143299/bitcoin-etfs-will-see-hundreds-of-billions-in-inflows-analyst-predicts">weekly net inflows</a> on record last week, totaling $3.13 billion, according to CoinShares.
What Happened: This surge brings year-to-date inflows to an unprecedented $37 billion, driven primarily by <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">Bitcoin ETFs</a>, which alone accounted for $3.12 billion, the report <a href="https://blog.coinshares.com/volume-210-digital-asset-fund-flows-weekly-report-1e294c6b2c70">stated</a>.
"This marks the largest single-week inflow we've ever recorded," stated James Butterfill, Head of Research at CoinShares. "Bitcoin's dominance in these inflows underscores the growing institutional confidence in the asset as a long-term investment."
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) attracted the lion's share of inflows, adding $3 billion to its investment products. 
However, the report also noted a $10 million inflow into short-Bitcoin products, reflecting some investor caution as Bitcoin prices hit new highs. 
Monthly inflows into short-Bitcoin products reached $58 million, the largest post since August 2022.
Altcoins also saw significant activity. 
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) outpaced Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) for the week, pulling in $16 million compared to Ethereum's $2.8 million. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42160774/microstrategy-is-the-bitcoin-magnet-says-bernstein-but-not-everybodys-sold-nothing-is-free-in-finance-says-one-analyst">MicroStrategy Is The &#8216;Bitcoin Magnet,&#8217; Says Bernstein, But Not Everybody&#8217;s Sold: &#8216;Nothing Is Free In Finance,&#8217; Says One Analyst</a>
Other notable altcoin inflows included XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) ($15 million), Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) ($4.1 million) and Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) ($1.3 million).
Despite Solana's weekly performance, Ethereum remains the stronger performer on a year-to-date basis.
The record U.S. inflows of $3.2 billion were partially offset by outflows in Europe, with Germany, Sweden, and Switzerland seeing withdrawals of $40 million, $84 million, and $17 million, respectively. 
"Recent price highs appear to have prompted profit-taking in these markets," Butterfill said. 
Meanwhile, more optimistic sentiment drove inflows in Australia ($9 million), Canada ($31 million), and Hong Kong ($30 million).
While single-asset products like Bitcoin and Solana saw strong demand, multi-asset investment products faced their second consecutive week of outflows, losing $10.5 million, indicating a preference for concentrated bets on specific digital assets rather than diversified portfolios.
CoinShares highlighted the stark contrast between Bitcoin ETFs and U.S. Gold ETFs, which attracted just $309 million in their debut year. 
Bitcoin's YTD inflows far outpace the gold product's early performance, emphasizing the increasing institutional appetite for crypto.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42145634/cboe-to-launch-cash-settled-bitcoin-index-options">Cboe To Launch Cash-Settled Bitcoin Index Options</a></li>
</ul>
Image: Shutterstock

$BTC

$ETH

$LINK

$LTC

$SOL

$XRP

Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week

WIIM

AMC shares are trading higher after the company announced record domestic revenue for pre-Thanksgiving weekend.

TD Cowen analyst Oliver Chen upgrades Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) from Hold to Buy and raises the price target from $14 to $16.

Upgrades

TD Cowen Upgrades Sally Beauty Holdings to Buy, Raises Price Target to $16

SRRK

Scholar Rock stock is trading higher after rival Biohaven's taldefgrobep for spinal muscular atrophy failed its Phase 3 study.

Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower. Goldman Sachs on Monday downgraded the EV maker to Sell and cut the price target. Here&#8217;s a look at what you <a href="https://www.benzinga.com/analyst-stock-ratings">need to know</a>.
What To Know: Goldman Sachs analyst Tina Hou downgraded Nio from <a href="https://www.benzinga.com/analyst-stock-ratings">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90 citing competitive pressures and a difficult path to profitability ahead. 
The Goldman analyst believes Nio is unfavorably positioned heading into 2025 given the slow production ramp of <a href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv">Onvo</a> and the company&#8217;s limited new model pipeline. Nio is expected to launch one new model in 2025. Hou expects Nio to be in a &#8220;relatively passive position&#8221; to try to keep up with launches from competitors. 
Nio&#8217;s compact Firefly SUV is expected to be launched in the first quarter, but Goldman anticipates limited volume of around 9,000 units in 2025. Moreover, the analyst expects the EV maker to have a tough time meeting margin targets as competition and scale act as headwinds. 
The analyst expects Nio to become operating cash flow positive in 2025 and free cash flow positive in 2029, versus prior estimates of 2026 and 2027, respectively. 
Hou cut profit estimates by 2% to 13% on lower sales volumes and and lowered the discounted free cash flow target by around 20%, arriving at a new price target of $3.90, suggesting approximately 18% downside potential. 
&#8220;We believe consensus hasn't sufficiently factored in the continued competition into the next few years, and the higher operating expenses associated with sales network expansion, which may not effectively translate into improving sales volume and efficiency, in our view,&#8221; the Goldman analyst said.
See Also: <a href="https://www.benzinga.com/24/11/42159490/elon-musks-tesla-hunts-top-talent-to-develop-software-for-robotaxi-optimus-robot-teleoperation-2">Elon Musk&#8217;s Tesla Hunts Top Talent To Develop Software For Robotaxi, Optimus Robot Teleoperation</a>
NIO Price Action: <a href="http://benzinga.com/quote/nio">Nio shares</a> were down 3% at $4.69 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Nio.

Downgrades

Global

Nio Analyst Sees Tougher Path To Profitability, Downgrades EV Maker To Sell: What You Need To Know

Larimar stock rallies 24% on FDA removal of partial clinical hold

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:<a href="https://investorplace.com/stock-quotes/pipr-stock-quote/">PIPR</a>) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. 



Piper Sandler may be the best bet for investors especially when you see where things are for biotech companies. The breakthrough drug discovery process can fail miserably. According to the American Society for Biochemistry and Molecular Biology, <a href="https://www.asbmb.org/asbmb-today/opinions/031222/90-of-drugs-fail-clinical-trials#:~:text=It%20takes%2010%20to%2015,candidates%20in%20clinical%20trials%20fail.">90% of all drug candidates</a> in clinical trials fail. Ouch!



Despite spending $1 billion on average, and waiting 10 to 15 years, most biotechs come up with nothing. That&rsquo;s why when they do succeed it is like hitting the lottery, because they have.



Piper Sandler believes they can post triple-digit returns over the next year. These Piper Sandler stocks are expected to grow by at least 100% in the next 12 months. Let&rsquo;s see why they feel confident these Piper Sandler stocks will double in price.



<h2>Piper Sandler Stocks to Buy: Context Therapeutics (CNTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/orthopedic-therapy-1600-imac-300x169.png" alt="Physiotherapist doing healing treatment on patient leg. Therapist wearing blue uniform. Osteopathy, Chiropractic leg adjustment. Orthopedic therapy. ATIP stck."><div>Source: Microgen / Shutterstock</div></div>Context Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntx-stock-quote/">CNTX</a>) is already off to the races. The biotech is up 80% so far in 2024 and has more than tripled over the past 12 months. Piper Sandler analyst Joseph Catanzaro initiated coverage of the stock last week with an overweight rating and set a market-high $4.50 per share one-year target price. Context stock currently trades around $2 per share, indicating 125% upside potential.



The analyst highlighted the potential of Context Therapeutics&rsquo; lead drug candidate, CTIM-76, which targets Claudin6 (CLDN6) in solid tumors. CLDN6 is one of the 27 family members of claudins that play an important role in tight adherence epithelial cell sheets that plays a significant role in cancer start and progression.



According to Investing.com CTIM-76 shows indications it <a href="https://www.investing.com/news/company-news/piper-sandler-bullish-on-context-therapeutics-stock-cites-ctim76-program-93CH-3443404">could be effective against</a> a broad range of CLDN6 expressions. That might let it be an effective therapy against different types of cancer, including ovarian and non-small cell lung cancer. Piper Sandler was bullish about the treatment&rsquo;s prospects heading into clinical testing.



Of course, Context Therapeutics is a pre-revenue stage company so its stock is going to be volatile but the market is backing this stock today.



<h2>Revance Therapeutics (RVNC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/health-medical-heart-1600-300x169.jpg" alt="hands holding a red heart shape against blue background symbolizing health"><div>Source: shutterstock.com/Anastasia Zagoruyko</div></div>Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvnc-stock-quote/">RVNC</a>) though he lowered the one-year price target from $20 per share to $11 per share. That is still a 263% implied upside in the stock price.



Unlike Context Therapeutics, Revance does generate revenue from the sale of Daxxify, an alternative to the better known Botox made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>). The treatment lasts between six months and nine months whereas Botox averages three to four months.



First-quarter <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm">revenue jumped 13%</a> to $51.9 million on higher Daxxify sales, which hit $22 million. Botox generates about $2 billion annually for AbbVie. Revance generated $29 million in sales of its RHA Collection, or Resilient Hyaluronic Acid, the only hyaluronic acid filler approved by the FDA for dynamic facial lines, wrinkles and folds. Daxxify is now also FDA-approved for the treatment of adults with cervical dystonia, a painful condition that causes the neck muscles to contract involuntarily, which causes the head to twist or turn to one side.



However, Revance stock has been on a long slide lower. Shares are down 65% in 2024 and over 90% for the past year. The stock collapsed after Revance posted bigger than expected losses last year and then continued falling after the biotech said it was <a href="https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/">cutting prices on Daxxify</a> to better compete against Botox. It likely plays into why the Piper Sandler analyst nearly halved his price target.



<h2>Design Therapeutics (DSGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>Design Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsgn-stock-quote/">DSGN</a>) went the other way when analyst Yasmeen Rahimi doubled her price target from $6 per share to $12 per share. She also upgraded her rating from neutral to overweight. Rahimi says the biotech has a diversified and innovative pipeline that provides a solid foundation for future growth.&nbsp;Trading at around $4.50 per share, the price target implies 167% growth ahead.



The analyst maintains the stock is value-priced yet offers solid financials and sufficient cash on hand to finance its drug development program. She believes the outlook for that program is positive, with promising outcomes for its DT-216P2, DT-168, and the upcoming drug candidates for Huntington&rsquo;s disease and myotonic dystrophy 1.



&#8203;&#8203;DT-216P2 is for the treatment of Friedreich Ataxia, a hereditary disorder that affects some of the body&rsquo;s nerves. DT-168 is for Fuchs endothelial corneal dystrophy, an eye disease that attacks the endothelial layer of the cornea.



Shares of Design Therapeutics are up 69% in 2024.



On the date of publication, Rich Duprey held a LONG position in ABBV stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains/">The 100%+ Club: Piper Sandler&#8217;s 3 Top Picks for Triple-Digit Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Lexeo stock drops 24% amid Friedreich Ataxia study results

Design Therapeutics GAAP EPS of -$0.21

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) yesterday and set a price target of $4...

RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)

Leerink Partners analyst Joseph Schwartz has reiterated their neutral stance on DSGN stock, giving a Hold rating on August 5. Joseph Schwartz has g...

Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress

RBC Capital Remains a Hold on Design Therapeutics (DSGN)

Design Therapeutics GAAP EPS of -$0.23 beats by $0.02

Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Design Therapeutics (DSGN – Research Report) on November 7 and set a price tar...

Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges

ABBV

ALPMF

ALPMY

BIIB

CNTX

DSGN

LRMR

LXEO

PIPR

PRME

PTCT

RVNC

SLDB

VYGR

Health Care

Press Releases

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Earnings

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Comments

Design Therapeutics

Vendite allo scoperto

Design Therapeutics (NASDAQ:DSGN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO